Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Yang J et al. | Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506. | 1999 | Pathol. Int. | pmid:10355966 |
Zarifian A et al. | Cyclosporine-associated thrombotic microangiopathy in renal allografts. | 1999 | Kidney Int. | pmid:10354295 |
Murata M et al. | A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. | 1999 | Br. J. Haematol. | pmid:10354150 |
Möller A et al. | The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. | 1999 | Drug Metab. Dispos. | pmid:10348790 |
Araki T et al. | Increases in [3H]FK-506 and [3H]L-N(G)-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation. | 1999 | Metab Brain Dis | pmid:10348311 |
Oddis CV et al. | Tacrolimus in refractory polymyositis with interstitial lung disease. | 1999 | Lancet | pmid:10347992 |
Siemann G et al. | Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. | 1999 | Mol. Pharmacol. | pmid:10347253 |
Boehringer M et al. | Kaposi's sarcoma after renal transplantation: treatment with liposomal doxorubicin. | 1999 | Nephrol. Dial. Transplant. | pmid:10344407 |
Tacrolimus in the prevention of graft rejection: new indication. Helpful alternative to ciclosporin. | 1998 | Prescrire Int | pmid:10342948 | |
Dresske B et al. | WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. | 1998 | Transpl. Immunol. | pmid:10342738 |